Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Narrow Excision Versus Wide Excision for the Treatment of Adults With Invasive Cutaneous Melanoma, ICEMAN Trial
Not Applicable
Recruiting
- Conditions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1000
- Registration Number
- NCT06673095
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06562777
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- Drug: Gonadotropin Releasing Hormone Agonists and AntagonistsDrug: BicalutamideProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingBiological: PembrolizumabOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Bone Scan
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT06528210
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06504459
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT06398587
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT06357182
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT06357676
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Examining Arts as Therapy in Children With Cancer, CREATe Trial
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 72
- Registration Number
- NCT06342453
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 110
- Registration Number
- NCT06335966
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2024. All Rights Reserved by MedPath